Barriers to Increasing Prescription Drug Monitoring Program Use: A Multidisciplinary Perspective
- PMID: 36728156
- PMCID: PMC10349893
- DOI: 10.1097/CIN.0000000000000997
Barriers to Increasing Prescription Drug Monitoring Program Use: A Multidisciplinary Perspective
Abstract
Prescription drug monitoring programs are implemented through individual state policies and are one solution to curb the opioid crisis. The objectives of this study are to: (1) describe the multidisciplinary experiences using this program in practice; (2) identify limitations of the program and the desired features for improvement; and (3) characterize expectations for improved access when prescription drug monitoring programs are embedded in the electronic health record. A qualitative descriptive study design used semistructured interviews of 15 multidisciplinary healthcare providers. Textual data were analyzed using content analysis. Results showed the prescription drug monitoring program was helpful to decision-making processes related to opioid prescribing and referral to treatment; there were barriers limiting healthcare providers' use of the prescription drug monitoring program; preferences were delineated for integrating prescription drug monitoring program into electronic health record; and recommendations were provided to improve the program and increase use. In conclusion, the prescription drug monitoring program was viewed as useful in making strides to reduce the impact of inappropriate opioid prescribing in our country. By engaging a multidisciplinary group of healthcare providers, solutions were offered to improve the interface and function of the prescription drug monitoring program to assist in increasing use.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Research reported in this publication was supported by the Iowa’s Opioid State Targeted Response Project Grant, Substance Abuse and Mental Health Administration, Iowa Board of Pharmacy (Contract Subgrant DSP Item # 1872100-CG, PI: Witry). This work was also partially supported by: National Institute on Drug Abuse (K23DA043049, PI: St. Marie). Dr. Reist has no conflict of interest.
References
-
- Bureau of Justice Assistance, U.S. Department of Justice. Prescription Drug Monitoring Program/Training and Technical Assistance Center. 2021. Accessed from https://www.pdmpassist.org/pdf/PDMP%20Policies%20and%20Capabilities%2020...
-
- Castillo-Carniglia A, Ponicki W, Gaidus A, Gruenewald P, Marshall BDL, Fink DS, Martins SS, Rivera-Aguirre A, Wintemute GJ, Cerdá M. Prescription drug monitoring programs and opioid overdoses: Exploring sources of heterogeneity. Epidemiol. 2019;30(2):212–20. doi: 10.1097/EDE.0000000000000950 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
